OncoMatch/Clinical Trials/NCT04776395
Iberdomide Alone or in Combination With Dexamethasone for the Treatment of Intermediate- or High-Risk Smoldering Multiple Myeloma
Is NCT04776395 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Dexamethasone and Iberdomide Hydrochloride for smoldering plasma cell myeloma.
Treatment: Dexamethasone · Iberdomide Hydrochloride — This phase II trial studies the effects of iberdomide when given alone or in combination with dexamethasone in treating intermediate or high-risk smoldering multiple myeloma patients. Immunotherapy with iberdomide may induce changes in body's immune system and may interfere with the ability of cancer cells to grow and spread. Dexamethasone is a synthetic steroid (similar to steroid hormones produced naturally in the adrenal gland), and is used with other drugs in the treatment of some types of cancer. Giving iberdomide with dexamethasone my improve time to progression to symptomatic myeloma with improved tolerability.
Check if I qualifyExtracted eligibility criteria
Cancer type
Multiple Myeloma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: treatment for plasma cell disorder
Prior or ongoing treatment for plasma cell disorder
Lab requirements
Blood counts
ANC >= 1500/uL; Hgb > 11 g/dL; Platelet count >= 100,000 cells/mm^3 and must be platelet and PRBC transfusion independent with no G-CSF to ensure eligibility within 8 weeks of screening
Kidney function
Estimated creatinine clearance >= 30 mL/min as defined by CKD-EPI or Cockcroft-Gault
Liver function
Total bilirubin < 2 mg/dL except in subjects with congenital bilirubinemia such as Gilbert syndrome, in which case direct bilirubin <= 2 times the institutional upper limit of normal is required; AST and ALT < 2.5 times the institutional upper limit of normal
Cardiac function
Left ventricular ejection fraction >= 40%
ANC >= 1500/uL; Hgb > 11 g/dL; Platelet count >= 100,000 cells/mm^3 and must be platelet and PRBC transfusion independent with no G-CSF to ensure eligibility within 8 weeks of screening; Estimated creatinine clearance >= 30 mL/min as defined by CKD-EPI or Cockcroft-Gault; Total bilirubin < 2 mg/dL except in subjects with congenital bilirubinemia such as Gilbert syndrome, in which case direct bilirubin <= 2 times the institutional upper limit of normal is required; AST and ALT < 2.5 times the institutional upper limit of normal; Left ventricular ejection fraction >= 40%
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Emory University Hospital/Winship Cancer Institute · Atlanta, Georgia
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify